Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Choosing BTKi or BCL2i or Combination Therapy for 1L CLL

Danielle Brander

Clinical Practice Updates in CLL/SLL

Integrity CE

M. Cortese, D. Wallace, A. Niu

1L Therapy in CLL: What Are the Best Options?

SOHO Brazil 2024

J. Burger

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

3L in CLL: The Best Options in a Patient Double-Refractory to Covale…

SOHO Brazil 2024

J. Burger

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

Sequencing Therapies in CLL: The Importance of First-Line Treatment …

Nicole Lamanna

CLL Treatment Sequencing: The Importance of First Choice

City of Hope

S. Rosen

Tafasitamab + Lenalidomide vs. CIT for Transplant-Ineligible R/R DLB…

Patrizia Mondello

Debates in CLL: Continuous or Finite Duration Therapy

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Managing R/R LBCL Patients Treated With Pola-R-CHP in 1L and Are CAR…

University of Colorado Cancer Center

M. Kamdar

Considering Alternatives to CAR-T in R/R DLBCL

Julio Chavez

Practice-Changing Updates in Indolent B-Cell Lymphomas

Massachusetts General Hospital Cancer Center

J. Soumerai

Tafasitamab/Lenalidomide for DLBCL: Which Patients and What to Expect

Amit Mehta

Single vs. Multiple Agents in 2L Therapy for CLL

SOHO Brazil 2024

J. Burger

Bispecifics for LBCL: Guidance for Management of Toxicities in the C…

UChicago Medicine

J. Crombie

Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and E…

2024 ASCO® Annual Meeting Insights Hub

K. Rogers, J. Woyach

The Next Frontier of Targeted Therapy in Lymphoma

UChicago Medicine

K. Maddocks